Sino Biological Unveils XPressMAX™ Kit to Revolutionize Antibody Drug Discovery
In an exciting development for the field of biotechnology, Sino Biological, Inc. has unveiled its groundbreaking XPressMAX™ Cell-Free Protein Synthesis Kit. This innovative product is designed to boost the process of antibody drug discovery, particularly through the utilization of artificial intelligence (AI). The XPressMAX™ kit offers a significant leap forward by allowing researchers to carry out protein synthesis without the limitations typically associated with cell-based systems.
What makes the XPressMAX™ kit truly remarkable is its ultra-fast synthesis time, which can complete processes in just three hours. This rapid turnaround is ideal for today's fast-paced research environments, where speed is crucial for keeping up with the demands of high-throughput screening pipelines. The integration of this kit with AI-driven platforms promises to streamline workflows, enabling researchers to identify and optimize antibody candidates more efficiently than ever before.
This self-contained kit operates on an E. coli lysate, which comes fully supplied with all essential components required for transcription and translation. By allowing protein synthesis directly from plasmid or PCR templates, XPressMAX™ significantly lowers the hurdles often faced during protein expression, thus ensuring a smoother research process.
Additionally, the kit supports the synthesis of complex proteins, such as single-chain variable fragments (scFv), VHH, and Fab, as well as Miniproteins, making it exceptionally versatile. Sino Biological has demonstrated the efficacy of XPressMAX™ by establishing a high-throughput platform capable of validating over 2,000 scFv/VHH molecules within a short timeframe of three to four weeks—a timeline that aligns perfectly with the rapid iterations demanded by AI technologies.
In a statement from Dr. Rob Burgess, the Chief Business Officer of Sino Biological US, the importance of this innovation is clear: "Our XPressMAX™ Kit is a significant advancement in the tools and reagents available for next-generation therapeutic discovery. By harnessing the power of both rapid protein expression and intelligent screening, we are supporting our partners in drastically reducing their antibody discovery timelines without sacrificing quality."
Dr. Jie Zhang, the General Manager at Sino Biological, further added, "As AI continues to revolutionize the landscape of antibody screening, it is paramount for expression systems to match that speed and throughput. With XPressMAX™, we achieve a remarkable expression rate of over 99% for challenging proteins within a minimal time frame."
For researchers interested in exploring the XPressMAX™ Cell-Free Protein Synthesis Kit, detailed information can be found on Sino Biological’s official website. The company also offers free samples for those looking to experience the benefits of this pioneering technology first-hand, thereby encouraging widespread adoption within the scientific community.
Sino Biological, a global leader in the production of recombinant proteins and antibodies, is dedicated to providing tailored solutions for researchers across the globe. With facilities such as the US-based Center for Bioprocessing located in Houston and its Canadian partner, SignalChem Biotech, the company aims to meet the diverse and evolving needs of research professionals. An unwavering commitment to quality ensures that all products adhere to stringent safety and efficacy standards, fostering trust in each offering.
As the journey of antibody discovery continues to evolve, innovations such as the XPressMAX™ Cell-Free Protein Synthesis Kit signal a promising future where researchers can achieve their goals faster and more effectively than ever before. This kit not only showcases Sino Biological’s leadership in recombinant technology but also illustrates the ongoing synergy between biotechnology and artificial intelligence, setting the stage for a new era of medical advancements.
What makes the XPressMAX™ kit truly remarkable is its ultra-fast synthesis time, which can complete processes in just three hours. This rapid turnaround is ideal for today's fast-paced research environments, where speed is crucial for keeping up with the demands of high-throughput screening pipelines. The integration of this kit with AI-driven platforms promises to streamline workflows, enabling researchers to identify and optimize antibody candidates more efficiently than ever before.
This self-contained kit operates on an E. coli lysate, which comes fully supplied with all essential components required for transcription and translation. By allowing protein synthesis directly from plasmid or PCR templates, XPressMAX™ significantly lowers the hurdles often faced during protein expression, thus ensuring a smoother research process.
Additionally, the kit supports the synthesis of complex proteins, such as single-chain variable fragments (scFv), VHH, and Fab, as well as Miniproteins, making it exceptionally versatile. Sino Biological has demonstrated the efficacy of XPressMAX™ by establishing a high-throughput platform capable of validating over 2,000 scFv/VHH molecules within a short timeframe of three to four weeks—a timeline that aligns perfectly with the rapid iterations demanded by AI technologies.
In a statement from Dr. Rob Burgess, the Chief Business Officer of Sino Biological US, the importance of this innovation is clear: "Our XPressMAX™ Kit is a significant advancement in the tools and reagents available for next-generation therapeutic discovery. By harnessing the power of both rapid protein expression and intelligent screening, we are supporting our partners in drastically reducing their antibody discovery timelines without sacrificing quality."
Dr. Jie Zhang, the General Manager at Sino Biological, further added, "As AI continues to revolutionize the landscape of antibody screening, it is paramount for expression systems to match that speed and throughput. With XPressMAX™, we achieve a remarkable expression rate of over 99% for challenging proteins within a minimal time frame."
For researchers interested in exploring the XPressMAX™ Cell-Free Protein Synthesis Kit, detailed information can be found on Sino Biological’s official website. The company also offers free samples for those looking to experience the benefits of this pioneering technology first-hand, thereby encouraging widespread adoption within the scientific community.
Sino Biological, a global leader in the production of recombinant proteins and antibodies, is dedicated to providing tailored solutions for researchers across the globe. With facilities such as the US-based Center for Bioprocessing located in Houston and its Canadian partner, SignalChem Biotech, the company aims to meet the diverse and evolving needs of research professionals. An unwavering commitment to quality ensures that all products adhere to stringent safety and efficacy standards, fostering trust in each offering.
As the journey of antibody discovery continues to evolve, innovations such as the XPressMAX™ Cell-Free Protein Synthesis Kit signal a promising future where researchers can achieve their goals faster and more effectively than ever before. This kit not only showcases Sino Biological’s leadership in recombinant technology but also illustrates the ongoing synergy between biotechnology and artificial intelligence, setting the stage for a new era of medical advancements.
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.